The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study

Daphine Namara¹, Jeremy I Schwartz¹,2, Andrew K Tusubira¹, Willi McFarland³, Caroline Birungi⁴, Fred C Semitala⁴ and Martin Muddu⁴

Abstract
Emerging evidence suggests a possible association between hyperglycemia and dolutegravir (DTG), a preferred first-line antiretroviral agent in sub-Saharan Africa (SSA). There is need for rigorous studies to validate this association in the face of increasing DTG use and burden of non-communicable diseases among people living with HIV (PLHIV). We conducted a case–control study to assess the risk of hyperglycemia associated with use of DTG among PLHIV attending Mulago ISS Clinic in Kampala. Cases had hyperglycemia while controls had no hyperglycemia as confirmed by fasting plasma glucose and oral glucose tolerance tests. Demographic, laboratory, and clinical data were collected using interviewer-administered questionnaires and medical record abstraction. Analysis compared cases and controls on DTG use prior to diagnosis of hyperglycemia while controlling for potential confounders using multivariable logistic regression. We included 204 cases and 231 controls. In multivariable analysis, patients with prior DTG use had seven times greater odds of subsequent diagnosis of hyperglycemia compared to those who had non-DTG-based regimens (adjusted odds ratio [aOR] 7.01, 95% CI 1.96–25.09). The odds of hyperglycemia also increased with age (56 years and above vs. 18–35, aOR 12.38, 95% CI 3.79–40.50) and hypertension (aOR 5.78, 95% CI 2.53–13.21). Our study demonstrates a strong association between prior DTG exposure and subsequent diagnosis of hyperglycemia. Given the benefits of DTG, wide-scale use, and the growing burden of diabetes mellitus (DM) in SSA, there is need for systematic screening for hyperglycemia and consideration of alternate regimens for those at risk for DM.

Keywords
Hyperglycemia, diabetes mellitus, dolutegravir, HIV, Uganda

Date received: 23 February 2022; accepted: 12 September 2022

Introduction
Increased access to anti-retroviral therapy (ART) has led to a reduction in acquired immunodeficiency syndrome (AIDS)-related deaths and an increased life expectancy of persons living with HIV (PLHIV) globally.¹,² However, with increasing life expectancy, PLHIV are faced with an increased risk of chronic non-communicable diseases (NCDs) such as diabetes mellitus (DM) and cardiovascular diseases (CVD).³,⁴ Additionally, use of ART has been shown to increase the risk of some NCDs among PLHIV.⁵,⁶ For example, the protease inhibitors (PIs) have been shown to increase the risk of DM.⁷,⁸

To increase the safety and effectiveness of HIV treatment, newer ART medications that are better tolerated have
emerged over the past decades.9,10 Dolutegravir (DTG) is a relatively new ART agent that belongs to the class of integrase inhibitors. It has superior potency for suppressing HIV viral load, a higher barrier to HIV resistance, and better tolerability compared to older ART such as the non-nucleoside reverse transcriptase inhibitors (NNRTIs).11–13 DTG-based ART regimens are progressively replacing efavirenz (EFV) containing ART regimens, the once preferred first-line ART.11 Due to these benefits, the World Health Organization (WHO) recommended DTG as the preferred first- and second-line ART for all adults, adolescents and children and DTG-based ART has been adopted in many low- and middle-income countries.14 Following WHO’s recommendation, the Uganda Ministry of Health (MoH) in its 2018 HIV treatment guidelines recommended the rollout of DTG-based ART as the preferred first- and second-line ART in the country.15 By the end of 2018, over 17 countries in sub-Saharan Africa had adopted and scaled up DTG-based ART.16

Despite its benefits, emerging evidence from case reports, case series, and clinical trials have suggested an association between DTG and disorders of glucose metabolism such as hyperglycemia.17–20 A more recent cross-sectional study conducted in Zambia found that when compared to NNRTI’s, DTG-based ART was associated with double the risk of developing metabolic syndrome among PLHIV; metabolic syndrome consists of hyperglycemia, hypertension, and dyslipidemia among other parameters all of which are known to increase the risk of DM.21 In Uganda and throughout SSA, where DTG is being widely rolled out and there is an increasing burden of NCDs among PLHIV and the general population, there is a paucity of information on the association between use of DTG-based ART and hyperglycemia.4 Those who develop hyperglycemia following use of DTG-based ART may need to be considered for alternate ART regimens, such as NNRTI-based which are better tolerated in this regard.15 Because changing the first- and second-line ART recommendations for persons at risk for DM would have profound implications for HIV care in SSA, there is great need for rigorous studies to validate the association between DTG and hyperglycemia. To this aim, we conducted a case–control study among adult PLHIV and receiving care at Mulago Immune Suppression Syndrome (ISS) clinic in Kampala, Uganda to determine the risk of hyperglycemia associated with use of DTG-based ART.

Methods

Study setting

The study was conducted at Mulago ISS clinic in Kampala, the largest HIV care center in Uganda. The clinic provides comprehensive HIV services to over 16,500 adults, adolescents, and children. Mulago ISS clinic adopted the use of DTG in March 2018 following the Uganda MoH guidelines for HIV treatment and prevention. Currently more than half of the total patient population is managed with DTG-based ART.

Study design

We conducted an unmatched case–control study to assess the risk of hyperglycemia associated with use of DTG-based ART among adult PLHIV who were receiving care from Mulago ISS clinic.

Definition of cases and controls

True cases were defined as PLHIV aged 18 years and above who were on ART, receiving HIV care from Mulago ISS clinic, and had hyperglycemia as confirmed by fasting plasma glucose (FPG) test of ≥ 100 mg/dl or 2-h oral glucose tolerance test (OGTT) of ≥ 140 mg/dl. To strengthen the inference of cause before effect, we excluded all cases whose diagnosis of hyperglycemia was made or known prior to March 2018 (i.e., when DTG was introduced at the clinic). True controls were defined as PLHIV aged 18 years and above who were on ART, receiving HIV care from Mulago ISS clinic, and had normal FPG of less than 100 mg/dl or a normal 2-h OGTT of less than 140 mg/dl. Pregnant women were excluded from the study because they were initially not eligible for DTG use in early 2018 due to the suspected risk of teratogenicity. Although they were later declared eligible in the Uganda MoH HIV treatment guidelines of 2020, there may persist some bias against its prescription during pregnancy.15 Additionally, recent studies emphasize the need to be cautious when prescribing DTG to pregnant women and this may also contribute to the bias against its prescription during pregnancy.25

ART regimens

ART regimens were categorized into DTG-based ART and non-DTG-based ART. DTG-based regimens were all ART regimens that contained DTG in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir (TDF), abacavir (ABC), or zidovudine (AZT). Non-DTG-based ART were all regimens that consisted of two NRTIs in combination with another anti-retroviral drug from the NRTIs class such as EFV, nevirapine (NVP), or from the protease inhibitors class such as lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).

Identification of cases and controls

To identify cases, we reviewed clinical and laboratory records to find patients with documented evidence of
hyperglycemia or use of diabetic medication such as oral hypoglycemics or insulin. Additionally, we identified those who presented at the triage area and consultation rooms for clinicians with signs and symptoms of hyperglycemia. For every case identified, one control was randomly selected from the electronic health record at Mulago ISS clinic, and their clinical records were reviewed to rule out documented evidence of hyperglycemia.

Recruitment of cases and controls
All identified cases and controls were approached, and those who consented to participate in the study were subjected to an FPG test and a 2-h oral OGTT to confirm them as true cases or controls. We recruited participants over a period of 2 months (February-April 2021). For efficiency of recruitment and to enable examination of other associations with hyperglycemia among PLHIV, cases and controls were not matched on age, sex, or other clinical conditions. These potential confounding factors were controlled for through multivariable regression analysis.

Laboratory procedures
We instructed consenting participants to fast for at least 8 hours prior to the glucose tests on the following morning. An FPG test and a 2-h OGTT were done by trained personnel at the clinic according to the 2021 American Diabetes Association guidelines.23

Data collection
We obtained data on socio-demographic characteristics, lifestyle, and medical history from individual participants using interviewer-administered questionnaires. We also measured and recorded participants’ blood pressure using a validated automatic blood pressure machine, height using a stadiometer, and weight using a balanced scale. We cross-checked information on the medical history, ART regimens, and dates of ART initiation by reviewing participants’ clinical records.

Ethical approval
The study protocol was reviewed and approved by the Institutional Review Boards of The AIDS Support Organization (TASO, approval number #TASOREC/078/2022-UG-REC-009), the Uganda National Council of Science and Technology (UNCST, #HS1077ES), and Yale University (#2000029496). All procedures performed in the study that involved human participants followed the ethical standards of the institutional and/or national research committee. We obtained written informed consent from all participants.

Statistical analysis
Our analysis entailed describing cases and controls, cross-tabulations, and estimation of bivariate and multivariable logistic regression models. We used chi-square tests to determine significant differences between cases and controls across demographic and clinical characteristics as well as on the main exposure variables of past and current DTG use. We tested for DTG’s association with hyperglycemia while adjusting for other potential associations such as age, sex, increasing BMI, and hypertension. Using bivariate logistic regression analysis, we obtained crude odds ratios (ORs) showing the strength of association between the dependent variable (hyperglycemia) and independent variables. We used multivariable logistic regression analysis to control for confounders and determine other factors associated with hyperglycemia among PLHIV. Variables that were significant in bivariate comparisons at $p < .05$, those found to be confounding in our analysis, and variables determined from literature to be associated with hyperglycemia were entered into the multivariable models to obtain adjusted estimates. Collinear variables were not included in the model. We used the Hosmer and Lemeshow’s goodness of fit and likelihood ratio tests to identify the final model. To assess the robustness of the final model, forward and backward stepwise approaches to model selection were found to converge on the same set of predictor variables. We considered an alpha of 0.05 for the level of significance and 95% confidence interval to test for the association of prior DTG use and subsequent hyperglycemia. All data analyses were conducted using STATA software version 16.

Results
Of 473 patients identified and approached, 456 consented to participate in the study including 218 cases and 238 controls. Twenty-one (14 cases and 7 controls) did not complete confirmatory tests for hyperglycemia and were excluded, leaving 435 participants (204 cases and 231 controls) for analysis. Significant differences existed between cases and controls in the variables of education, current BMI, having hypertension as a comorbidity, previous ART regimen, and current ART regimen (Table 1). Among the 204 cases, 54 (26.5%) had hyperglycemic levels that were diagnostic of prediabetes with 150 (73.5%) being diagnostic of DM. Of note, 75 (40.1%) cases previously on DTG were changed to other ART regimens after being diagnosed with hyperglycemia.

Table 2 presents the multivariable logistic regression analysis assessing the association of prior DTG use and hyperglycemia while adjusting for age, current BMI, hypertension as a comorbidity, total duration of ART use, and current ART regimen. Patients with prior DTG use had seven-fold greater odds of having hyperglycemia compared
to those who had non-DTG based regimens as their previous ART (aOR 7.01, 95% CI 1.96–25.09). The odds of having hyperglycemia also increased with older age (56 and above vs. 18–35 years, aOR 12.38, 95% CI 3.79–40.50) and having hypertension as a comorbidity (aOR 5.78, 95% CI 2.53–13.21).

**Table 1.** Characteristics of cases (hyperglycemia) and controls (no hyperglycemia), patients in HIV in care, Uganda, 2020–2021.

| Variable                              | Cases (hyperglycemia) | Controls (no hyperglycemia) | p-value |
|---------------------------------------|-----------------------|-----------------------------|---------|
|                                       | n=204 (%)             | n=231 (%)                   |         |
| **Age categories (in years)**         |                       |                             |         |
| 18 to 35                              | 12 (5.9)              | 63 (27.3)                   | <0.001  |
| 36 to 45                              | 57 (27.9)             | 92 (39.8)                   |         |
| 46 to 55                              | 90 (44.1)             | 59 (25.5)                   |         |
| 56 and above                          | 45 (22.1)             | 17 (7.4)                    |         |
| **Sex**                               |                       |                             |         |
| Male                                  | 68 (33.3)             | 67 (29.0)                   | 0.330   |
| Female                                | 136 (66.7)            | 164 (71.0)                  |         |
| **Level of education**                |                       |                             |         |
| No education                          | 28 (13.7)             | 22 (9.5)                    | 0.041   |
| Primary                               | 89 (43.6)             | 130 (56.3)                  |         |
| Secondary                             | 62 (30.4)             | 62 (26.8)                   |         |
| Tertiary                              | 25 (12.3)             | 17 (7.4)                    |         |
| **Most recent viral load**            |                       |                             | 0.92    |
| Suppressed (<1000 copies/ml)          | 186 (91.2)            | 210 (90.9)                  |         |
| Non-suppressed (>1000)                | 18 (8.8)              | 21 (9.1)                    |         |
| **Current BMI (kg/m^2)**              |                       |                             |         |
| Underweight (under 18.5)              | 16 (7.8)              | 16 (6.9)                    | 0.009   |
| Normal weight (18.5 to 25)            | 58 (28.4)             | 100 (43.3)                  |         |
| Overweight (25 to 30)                 | 79 (38.8)             | 77 (33.3)                   |         |
| Obese (over 30)                       | 51 (25.0)             | 38 (16.5)                   |         |
| **Hypertension as comorbidity**       |                       |                             |         |
| Has hypertension                      | 68 (33.3)             | 12 (5.2)                    | <0.001  |
| No hypertension                       | 136 (66.7)            | 219 (94.8)                  |         |
| **Previous ART regimen (n=398)**      |                       |                             |         |
| DTG based regimen                     | 75 (40.1)             | 4 (1.9)                     | <0.001  |
| Non-DTG based regimen                 | 112 (59.9)            | 207 (98.1)                  |         |
| **Current ART regimen**               |                       |                             |         |
| DTG based regimen                     | 83 (40.7)             | 212 (91.8)                  | <0.001  |
| Non-DTG based regimen                 | 121 (59.3)            | 19 (8.2)                    |         |
| **Total duration of ART use**         |                       |                             | 0.284   |
| Less than 5 years                     | 39 (19.1)             | 52 (22.5)                   |         |
| 5 to 10 years                         | 107 (52.5)            | 128 (55.4)                  |         |
| 11 and more years                     | 58 (28.4)             | 51 (22.1)                   |         |
| **Duration on DTG based regimen (n=365)** |                   |                             |         |
| Less than 1 year                      | 55 (36.0)             | 75 (35.4)                   | 0.892   |
| 1 to 2 years                          | 90 (58.8)             | 128 (60.4)                  |         |
| 3 or more years                       | 8 (5.2)               | 9 (4.2)                     |         |
| **History of gestational diabetes**   |                       |                             | 0.157   |
| Yes                                   | 0 (0)                 | 1 (1.0)                     |         |
| No                                    | 1 (1.0)               | 0 (0)                       |         |

*Analysis limited to participants who had prior use of other ART regimens.

*Analysis limited to participants who had used DTG.

ART = antiretroviral treatment; BMI = body mass index; DTG = Dolutegravir

**Discussion**

Our findings in a large HIV care center in an African setting corroborate evidence from prior case reports, case series, and randomised controlled trials that have suggested an association between DTG and deranged glucose...
The mechanism by which DTG causes deranged glucose metabolism is not well understood, although it is hypothesized that DTG causes insulin resistance by chelating magnesium ions which are needed as cofactors for effective action of insulin. Our findings indicate that PLHIV who had previously been prescribed DTG-based ART had seven times greater odds of having hyperglycemia compared to those who had been previously prescribed non-DTG ART regimens, even after controlling for potential confounders such as age, BMI, and hypertension as a co-morbidity. Notably, over 70% of the cases in our study had glucose levels that were diagnostic of DM. DM presents a great challenge to Uganda’s health care system, especially in HIV care clinics that remain underprepared to diagnose and manage DM, as is the case in other low-income countries. Based on unpublished case reports of hyperglycemia among PLHIV from various HIV care clinics in Uganda following initiation of DTG, the Uganda MoH recommended that all patients diagnosed with, or with risk factors for, DM should not be initiated on DTG. Those who develop DM while on DTG are also to be changed to alternate ART regimens. Our study findings collaborate this local evidence that these policy changes were justified. The timely change in policy also likely explains why many cases in this study were not continuing to use DTG-based ART; over 40% of the cases had been discontinued from DTG following the diagnosis of hyperglycemia.

The high number of hyperglycemia cases identified in our study indicates that gaps remain in baseline screening of patients for hyperglycemia prior to use of DTG but also the lack of consistent monitoring for those already using DTG. We used an FPG test and a 2-h OGTT to confirm the glycemic states of our study participants including those whose glucose levels qualified them as pre-diabetic. These assays are more reliable than random and fasting blood glucose tests often used in HIV care facilities in Uganda. Stakeholders in HIV service delivery should consider implementing the use of more reliable tests for hyperglycemia screening prior to initiation of DTG.

Consistent with prior studies, we also found that older PLHIV (particularly above 56 years) and those with hypertension were more likely to be diagnosed with hyperglycemia compared to younger patients and those without hypertension. Although BMI was not significantly associated with the occurrence of hyperglycemia in multivariable regression analysis controlling for other factors such as age and hypertension as a comorbidity; in bivariate analysis, PLHIV who were currently obese, or overweight were more likely to have hyperglycemia compared to those who had normal current BMI. These findings emphasize the need to screen these high-risk groups for hyperglycemia and

### Table 2. Factors associated with hyperglycemia, adult patients in HIV care, Kampala, Uganda, 2020–2021.

| Variable                      | Crude odds ratios | 95% Confidence interval | Adjusted odds ratios | 95% Confidence interval |
|-------------------------------|-------------------|--------------------------|----------------------|-------------------------|
| **Previous ART regimen**      |                   |                          |                      |                         |
| Non-DTG based regimen         | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| DTG based regimen             | 34.65             | 12.35–97.23*             | 7.01                 | 1.96–25.09*             |
| **Age categories (in years)** |                   |                          |                      |                         |
| 18 to 35                      | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| 36 to 45                      | 3.25              | 1.61–6.55*               | 3.91                 | 1.51–10.14*             |
| 46 to 55                      | 8.01              | 3.98–16.11*              | 9.23                 | 3.43–24.78*             |
| 56 and above                  | 13.90             | 6.05–31.94*              | 12.38                | 3.79–40.50*             |
| **Current BMI (kg/m²)**       |                   |                          |                      |                         |
| Underweight (under 18.5)      | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| Normal weight (18.5 to 25)    | 0.58              | 0.27–1.25                | 0.24                 | 0.77–0.74*              |
| Overweight (25 to 30)         | 1.03              | 0.48–2.19                | 0.59                 | 0.20–1.76               |
| Obese (over 30)               | 1.34              | 0.59–3.02                | 0.75                 | 0.24–2.39               |
| **Hypertension as a comorbidity** |                |                          |                      |                         |
| No hypertension               | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| Has hypertension              | 9.13              | 4.76–17.48*              | 5.78                 | 2.53–13.21*             |
| **Total duration of ART use** |                   |                          |                      |                         |
| Less than 5 years             | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| 5 to 10 years                 | 1.11              | 0.68–1.82                | 0.56                 | 0.25–1.26               |
| 11 and more years             | 1.52              | 0.87–2.66                | 0.68                 | 0.28–1.66               |
| **Current ART regimen**       |                   |                          |                      |                         |
| Non-DTG based regimen         | 1.0 (ref)         | 1.0 (ref)                |                      |                         |
| DTG based regimen             | 0.06              | 0.04–0.11                | 0.07                 | 0.03–0.16*              |

*p-value < 0.05
hypertension vigilantly and consistently prior to use of DTG and to improve access to routine blood glucose monitoring for patients while on DTG.

As with all case-control studies, causal interpretation of our results is limited compared to prospective studies and clinical trials. While we classified exposure as the use of DTG prior to the diagnosis of hyperglycemia (i.e., cause before effect), it is not certain if underlying hyperglycemia existed prior to initiating DTG in all cases. It is also possible that DTG may accelerate a person to develop hyperglycemia when they have an underlying disposition, a factor we are unable to conclusively speak to in our case-control study. Due to the retrospective nature of our study, and a lack of reliable medical records, we were limited in establishing whether hyperglycemia resolved after switching from DTG-with or without treatment for hyperglycemia. Additionally, due to this same limitation of retrospective nature of our study, we were unable to establish changes in weight in relation to DTG exposure for cases and controls. However, we acknowledge that weight gain has been associated with use of DTG-based ART and consequently to an increased risk of deranged glucose metabolism and type II DM among PLHIV.\(^\text{19}\) Additionally, the duration of DTG exposure prior to onset of hyperglycemia could not be accurately measured to determine a dose-response effect. We also acknowledge the limitation of incomplete control for confounders both measured and unmeasured as inherent in the case-control design.

Despite the limitations in deducing the precise timing of events, our study noted a sequence of cases having no prior history of hyperglycemia while using non-DTG-based ART, being switched to DTG-based ART following the national roll out of DTG, and then taking them off DTG after finding hyperglycemia. This sequence provides insights on a possible causal association. In the absence of local trials or data from prospective cohort studies, our retrospective approach, coupled with evidence from other settings, provides an efficient mechanism to validate proposed changes to local guidelines in ART regimens.

In conclusion, our study demonstrates a strong association between prior DTG exposure and the development of hyperglycemia. Given the great benefits of DTG, the wide-scale roll-out in SSA countries, and the growing burden of DM in these settings, our data weigh in favor of systematic screening for hyperglycemia prior to initiating DTG, routine glucose monitoring, and the consideration of alternate regimens for those at risk for DM.

**Acknowledgements**

We are grateful to the team at Uganda Initiative for Integrated Management of Non-Communicable Diseases (UNICD) as well as the team at Mulago ISS clinic for their invaluable support to this study.

**Author contributions**

DN, MM, JIS, WM, and AKT were responsible for the design of the study and interpretation of data. DN and AKT led data collection and interpretation. AKT and DN performed data analysis. CB and FCS participated in the design of the study and interpretation of data. All authors participated in writing the initial draft of the manuscript. DN, MM, JS, and WM participated in writing the final manuscript. All authors read and approved the final manuscript before submission.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this manuscript was supported by the US National Institutes of Health (NIH), Fogarty International Center under the Global Health Equity Scholars Consortium at Yale University (D43TW010540). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funder had no role in the study design, data collection, analysis, or interpretation. Daphine Namara had full access to all the data and had the final responsibility for the decision to submit the manuscript for publication.

**ORCID iDs**

Daphine Namara  https://orcid.org/0000-0003-4413-2745
Willi McFarland  https://orcid.org/0000-0002-4148-5660

**References**

1. HIV.gov. The Global HIV/AIDS Overview. Department of Health and Human Services, https://www.hiv.gov/federal-response/pepfar-global-aids/global-hiv-aids-overview(2021) (2021, accessed 6 August 2021).
2. Wandeler G, Johnson LF and Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. *Curr Opin HIV AIDS* 2016; 11(5): 492–500.
3. Casper C, Crane H, Menon M, et al. HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. *Major Infectious Diseases*. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank, 2017.
4. Cheza A, Tiou B and Zhou DT. Incidence of noncommunicable diseases (NCDs) in HIV patients on ART in a developing country: case of Zimbabwe’s Chitungwiza central hospital-a retrospective cohort study (2010–2019). *PLoS One* 2021; 16(5): e0252180.
5. Haregu TN, Setsew G, Elliott J, et al. National responses to HIV/AIDS and non-communicable diseases in developing countries: analysis of strategic parallels and differences. *J Public Health Res* 2014; 3(1): 99.
6. Kansiime S, Mwesigire D and Mugerwa H. Prevalence of noncommunicable diseases among HIV positive patients on
antiretroviral therapy at joint clinical research centre, Lubowa, Uganda. *PloS One* 2019; 14(8): e0221022.
7. Gómez-Vera J, de Alarcón A, Jiménez-Mejías ME, et al. Hyperglycemia associated with protease inhibitors in HIV-1-infected patients. *Clin Microbiol Infect* 2000; 6(7): 391–394.
8. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. *Diabetes Metab Res Rev* 2017; 33(6): 10.
9. Pau AK and George JM. Antiretroviral therapy: current drugs. *Infect Dis Clin North Am* 2014; 28(3): 371–402.
10. National Institute of Allergy and Infectious Diseases. Antiretroviral drug discovery and development. National Institutes of Health, https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development (2018, accessed 6 August 2021).
11. Phillips AN, Bansji-Matharu L, Venter F, et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. *Lancet HIV* 2020; 7(3): 193–200.
12. Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy, and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. *Lancet HIV* 2016; 3(11): 510–520.
13. Yoshinaga T, Miki S, Kawauchi-Miki S, et al. Barrier to resistance of dolutegravir in two-drug combinations. *Antimicrob Agents Chemother* 2019; 63(3): e02104–e02118.
14. World Health Organization. *Policy brief: update of recommendations on first- and second-line antiretroviral regimens*. World Health Organization, https://apps.who.int/iris/handle/10665/325892 (2019, accessed 6 August 2021).
15. Ministry of Health, Uganda. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda, https://elearning.idi.co.ug/pluginfile.php/5675/mod_page/content/24/Consolidated%20HIV%20and%20AIDS%20Guidelines%202020%20June%202030th.pdf (2020, accessed 6 August 2021).
16. Granich R, Gupta S, Kosicki L, et al. Dolutegravir and the universal antiretroviral regimen: Good may be the enemy of perfect [WEAD0304]. In: Presented at: 22nd International AIDS Conference, Amsterdam, Netherlands, 2018.
17. McLaughlin M, Walsh S and Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. *J Antimicrob Chemother* 2018; 73(1): 258–260.
18. Hailu W, Tesfaye T and Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. *Int Med Case Rep J* 2021; 14: 503–507.
19. McCann K, Shah S, Hindley L, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. *AIDS* 2021; 35(10): 1657–1665.
20. Lamorde M, Atwiine M, Owarwo NC, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. *Lancet HIV* 2020; 7(7): 461–462.
21. Hamooya BM, Mulenga LB, Masenga SK, et al. Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors. *Medicine (Baltimore)* 2021; 100(14): e25236.
22. Aekplakorn W, Tantayotai V, Numsangkul S, et al. Detecting Prediabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults. *J Diabetes Res* 2015; 2015:396505
23. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes. *Diabetes Care* 2020; 43(1): 14–31.
24. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. *Diabetes Care* 2021; 44(1): 15–33.
25. Zipursky J and Loutfy M. Dolutegravir for pregnant women living with HIV. *CMAJ* 2020; 192(9): 217–218.
26. Ntem-Mensah AD, Millman N, Jakharia N, et al. 345. Acute Onset diabetic ketoacidosis/hyperosmolar hyperglycemic state in patients taking integrase strand transfer inhibitors. *Open Forum Infect Dis* 2019; 6(2): 183–184.
27. Cogliandro1 V., Lapadula1 G., Squillace1 N., et al. New cases of diabetes dolutegravir-associated in HIV patients: a case series(P117). In: Presented at: 12th National Conference ICAR Italian Conference on AIDS and Antiviral Research, Riccione, Italy, 2020.
28. Kamal P and Sharma S. SUN-187 Dolutegravir Causing Diabetes. *J Endocr Soc* 2019; 3(1): 187.
29. Masuku SKS, Tsoka-Gwegweni JM and Sartorius B. The economic burden of HIV and type 2 diabetes comorbidity: Implications for care in countries with high burden of HIV. *J Diabetology* 2019; 10(3): 86–96.
30. Coelho AR, Moreira FA, Santos AC, et al. Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test - which method to choose for the diagnosis? *BMC Infect Dis* 2018; 18(1): 309.
31. Shankalala P, Jacobs C, Bosomprah S, et al. Risk factors for impaired fasting glucose or diabetes among HIV infected patients on ART in the Copperbelt Province of Zambia. *J Diabetes Metab Disord* 2017; 16: 29.